26 June 2024
26 June 2024
The company’s decision follows the independent committee's analysis that the trial is unlikely to meet its primary endpoints.
Research indicates that designing clinical trials with the patient in mind reduces recruitment times and enhances trial performance. Daniel J. Herron, a life sciences specialist, explains why one of the key factors in improving participant involvement is document readability.
The CRL found no problems with the efficacy, safety or labelling of ABBV-951.
From Pfizer’s Seagen acquisition to Sanofi’s deal with Provention Bio, Pharmaceutical Technology lists the highest value pharma mergers and acquisitions completed in 2023.
An open-label trial is currently assessing the safety, tolerability, and manufacturing feasibility of CT-0525.
ETH47 is a type III interferon-encoding mRNA drug that could be used to treat respiratory diseases including uncontrolled asthma.
The approval was based on the findings from the open-label, randomised, multicentre, global FLAURA2 Phase III trial.
The approval was supported by data from a Phase II/III study and a confirmatory Phase III clinical trial.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
